For The Better

The Boeing supplier continues to face financial challenges and quality control questions.

A Wall Street analyst sees defense profit margin improving and Pratt & Whitney overcoming the engine inspections issue.

Novo Nordisk might be best known for Ozempic, but the company just received positive news from the FDA for an entirely different drug.

This could be a buy-the-dip opportunity for long-term investors.

Nvidia has a bright future despite its already stellar performance.

Don’t jump on the bandwaggon too quickly.

A couple of years ago, Pfizer’s shares may have seemed like a sure thing. That may not be the case anymore.

The company’s valuation may be high but that doesn’t mean Eli Lilly is anywhere near its peak.

Rithm offers a big dividend, but there’s more to the business that investors should be aware of.

The furnishings retailer had some good news for investors on its quarterly update.

Oil majors continue to look like a good value even as the price of oil hovers around $80 a barrel.

After coming back to reality, On Holding might be worth a look.

Rivian’s new R2 and R3 both look great, but Rivian needs to build them before it can sell them (or profit from them).

Most retirees will notice a financial gap between their Social Security payout and their monthly expenses.

The robotic cleaning-device giant had more bad news for investors in its recent earnings update.

The creativity software specialist’s CEO touts the use of generative AI in delivering “groundbreaking innovation across our product portfolio.”

Tesla is failing to keep pace with the rest of the Magnificent Seven.

Companies that raised their dividends have outperformed the S&P 500 index with less volatility during the past five decades.

Databricks is one of the world’s most valuable start-ups, backed by a series of impressive investors, including Nvidia.

These companies’ shares are a bargain compared to their potential in tech.